BioStock: Evaxion unveils genetic adjuvant technology to boost vaccines

Evaxion Biotech continues to deliver in its efforts to develop novel cancer immunotherapies. After launching the new ObsERV AI drug discovery platform last month, the company has now introduced its genetic adjuvant technology to boost the effect of DNA and mRNA vaccines. At the same time, Evaxion has announced the successful completion of the phase I trial with the personalised cancer vaccine EVX-01. To discuss all of this, BioStock reached out to Evaxion’s CEO Per Norlén.

Read the full interview with Per Norlén at biostock.se:

https://www.biostock.se/en/2023/06/evaxion-unveils-genetic-adjuvant-technology-to-boost-vaccines/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/